Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hydroxychloroquine Prevents Congenital Heart Block Recurrence in Anti-Ro Pregnancies

Key clinical point: Hydroxychloroquine (Plaquenil) 400 mg/day starting by pregnancy week 10 reduces recurrence of congenital heart block in infants born to women with anti-Ro antibodies.

Major finding: Among antibody-positive women who had a previous pregnancy complicated by congenital heart block, the regimen reduced recurrence in a subsequent pregnancy from the expected historical rate of 18% to 7.4%, a more than 50% drop.

Study details: Open label, prospective trial with 63 subjects

Disclosures: The National Institutes of Health funded the work. The investigators had no relevant disclosures.

Citation:

Izmirly P et al. Arthritis Rheumatol. 2019;71(suppl 10). Abstract 1761.